These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1363260)

  • 41. Dofetilide, a novel class III antiarrhythmic agent.
    Rasmussen HS; Allen MJ; Blackburn KJ; Butrous GS; Dalrymple HW
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S96-105. PubMed ID: 1279316
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical implications of new studies in the treatment of benign, potentially malignant and malignant ventricular arrhythmias.
    Anderson JL
    Am J Cardiol; 1990 Jan; 65(4):36B-42B. PubMed ID: 2105050
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Drug-induced torsade de pointes.
    Raehl CL; Patel AK; LeRoy M
    Clin Pharm; 1985; 4(6):675-90. PubMed ID: 2416504
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dofetilide: a new drug to control cardiac arrhythmia.
    Elming H; Brendorp B; Pedersen OD; Køber L; Torp-Petersen C
    Expert Opin Pharmacother; 2003 Jun; 4(6):973-85. PubMed ID: 12783593
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Dofetilide: a class III-specific antiarrhythmic agent.
    Kalus JS; Mauro VF
    Ann Pharmacother; 2000 Jan; 34(1):44-56. PubMed ID: 10669186
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Canadian Cardiovascular Society atrial fibrillation guidelines 2010: rate and rhythm management.
    Gillis AM; Verma A; Talajic M; Nattel S; Dorian P;
    Can J Cardiol; 2011; 27(1):47-59. PubMed ID: 21329862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The side effect profile of class III antiarrhythmic drugs: focus on d,l-sotalol.
    MacNeil DJ
    Am J Cardiol; 1997 Oct; 80(8A):90G-98G. PubMed ID: 9354416
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Cardiac Arrhythmia Suppression Trial: Implications for nursing practice.
    Kellen JC; Ettinger A; Todd L; Brezsnyak ML; Campion J; McBride R; Thomas S; Corum J; Schron E
    Am J Crit Care; 1996 Jan; 5(1):19-25. PubMed ID: 8680488
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is it rational, reasonable or excessive, and consistently applied? One view of the increasing FDA emphasis on safety first for the release and use of antiarrhythmic drugs for supraventricular arrhythmias.
    Reiffel JA
    J Cardiovasc Pharmacol Ther; 2001 Oct; 6(4):333-9. PubMed ID: 11907635
    [No Abstract]   [Full Text] [Related]  

  • 50. Update: cardiac antiarrhythmic drugs.
    Liem LB; Kates RE
    Compr Ther; 1989 Apr; 15(4):17-27. PubMed ID: 2495883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Effects of amiodarone, sematilide, and sotalol on QT dispersion.
    Cui G; Sen L; Sager P; Uppal P; Singh BN
    Am J Cardiol; 1994 Nov; 74(9):896-900. PubMed ID: 7526675
    [TBL] [Abstract][Full Text] [Related]  

  • 52. New advances in class III antiarrhythmic drug therapy.
    Sager PT
    Curr Opin Cardiol; 1999 Jan; 14(1):15-23. PubMed ID: 9932203
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A review of the class III antiarrhythmic agents and their uses and implications for patient management.
    Todd DW
    J Oral Maxillofac Surg; 2003 Aug; 61(8):928-31. PubMed ID: 12905446
    [No Abstract]   [Full Text] [Related]  

  • 54. Myocardial repolarization and drugs. Impossibility to predict the dominance of anti-arrhythmic over pro-arrhythmic effects of drugs due to differential and ventricular electrical remodeling.
    Vos MA; Crijns HJ
    Anadolu Kardiyol Derg; 2001 Mar; 1(1):27-34. PubMed ID: 12122969
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Arrhythmia control by prolonging repolarization: the concept and its potential therapeutic impact.
    Singh BN
    Eur Heart J; 1993 Nov; 14 Suppl H():14-23. PubMed ID: 7904934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Beta-blocker prevention of proarrhythmia and proischemia: clues from CAST, CAMIAT, and EMIAT. Cardiac Arrhythmia Suppression Trial. Canadian Amiodarone Myocardial Infarction Arrhythmia Trial. European Myocardial Infarct Amiodarone Trial.
    Kennedy HL
    Am J Cardiol; 1997 Nov; 80(9):1208-11. PubMed ID: 9359552
    [No Abstract]   [Full Text] [Related]  

  • 57. Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model.
    Yoshida H; Sugiyama A; Satoh Y; Ishida Y; Yoneyama M; Kugiyama K; Hashimoto K
    Circ J; 2002 Aug; 66(8):758-62. PubMed ID: 12197602
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Pharmacologic and pharmacokinetic profile of class III antiarrhythmic drugs.
    Kowey PR; Marinchak RA; Rials SJ; Bharucha D
    Am J Cardiol; 1997 Oct; 80(8A):16G-23G. PubMed ID: 9354408
    [TBL] [Abstract][Full Text] [Related]  

  • 59. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach.
    Borggrefe M; Haverkamp W; Shenasa M; Hindricks G; Breithardt G
    J Cardiovasc Pharmacol; 1992; 20 Suppl 2():S32-40. PubMed ID: 1279307
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Class I antiarrhythmic drugs: mechanisms, contraindications, and current indications].
    Pott C; Dechering DG; Muszynski A; Zellerhoff S; Bittner A; Wasmer K; Mönnig G; Eckardt L
    Herzschrittmacherther Elektrophysiol; 2010 Dec; 21(4):228-38. PubMed ID: 21113605
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.